Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

被引：106

作者：

Avet-Loiseau, Herve ^{[1
,2
]}

Malard, Florent ^{[2
]}

Campion, Loic ^{[3
]}

Magrangeas, Florence ^{[2
]}

Sebban, Catherine ^{[4
]}

Lioure, Bruno ^{[5
]}

Decaux, Olivier ^{[6
]}

Lamy, Thierry ^{[7
]}

Legros, Laurence ^{[8
]}

Fuzibet, Jean-Gabriel ^{[9
]}

Michallet, Mauricette ^{[10
]}

Corront, Bernadette ^{[11
]}

Lenain, Pascal ^{[12
]}

Hulin, Cyrille ^{[13
]}

Mathiot, Claire ^{[14
]}

Attal, Michel ^{[15
]}

Facon, Thierry ^{[16
]}

Harousseau, Jean-Luc ^{[17
]}

Minvielle, Stephane ^{[2
]}

Moreau, Philippe ^{[18
]}

机构：

[1] Univ Hosp, Hematol Lab, Inst Biol, F-44093 Nantes, France

[2] INSERM, U892, Nantes, France

[3] Ctr Rene Gauducheau, Dept Stat, F-44035 Nantes, France

[4] Ctr Leon Berard, Dept Hematol, F-69373 Lyon, France

[5] Univ Hosp, Dept Hematol, Strasbourg, France

[6] Univ Hosp, Dept Internal Med, Rennes, France

[7] Univ Hosp, Dept Hematol, Rennes, France

[8] Univ Hosp, Dept Hematol, Nice, France

[9] Univ Hosp, Dept Internal Med, Nice, France

[10] Univ Hosp, Dept Hematol, Lyon, France

[11] Univ Hosp, Dept Hematol, Annecy, France

[12] Ctr Francois Baclesse, Dept Hematol, Rouen, France

[13] Univ Hosp, Dept Hematol, Nancy, France

[14] Inst Curie, Hematol Lab, Paris, France

[15] Univ Hosp, Dept Hematol, Toulouse, France

[16] Univ Hosp, Dept Hematol, Lille, France

[17] Ctr Rene Gauducheau, Dept Hematol, F-44035 Nantes, France

[18] Univ Hosp, Dept Hematol, Nantes, France

来源：

BLOOD | 2011年 / 117卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; C-MAF; MAINTENANCE; THALIDOMIDE; EXPRESSION; SURVIVAL; THERAPY; TRIAL; GENE;

D O I：

10.1182/blood-2010-07-295105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retro-spectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma. (Blood. 2011; 117(6): 2009-2011)

引用

页码：2009 / 2011

页数：3

共 50 条

[41] A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
Goldman-Mazur, Sarah
Jurczyszyn, Artur
Castillo, Jorge J.
Waszczuk-Gajda, Anna
Grzasko, Norbert
Radocha, Jakub
Bittrich, Max
Kortuem, K. Martin
Gozzetti, Alessandro
Usnarska-Zubkiewicz, Lidia
Davila Valls, Julio
Jayabalan, David S.
Niesvizky, Ruben
Kelman, Julia
Coriu, Daniel
Rosinol, Laura
Szukalski, Lukasz
Gonzalez-Calle, Veronica
Mateos, Maria V.
Jamroziak, Krzysztof
Hus, Iwona
Avivi, Irit
Cohen, Yael
Suska, Anna
Chappell, Aimee
Madduri, Deepu
Chhabra, Saurabh
Kleman, Ariel
Hari, Parameswaran
Delforge, Michel
Robak, Pawel
Gentile, Massimo
Kozlowska, Izabela
Goldberg, Stuart L.
Czepiel, Jacek
Silbermann, Rebecca
Olszewski, Adam J.
Barth, Peter
Mikala, Gabor
Chim, Chor S.
Dlugosz-Danecka, Monika
Grosicki, Sebastian
Vesole, David H.
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (05) : 503 - 509
[42] MYEOV is a prognostic factor in multiple myeloma
Moreaux, Jerome
Hose, Dirk
Bonnefond, Amelie
Reme, Thierry
Robert, Nicolas
Goldschmidt, Hartmut
Klein, Bernard
EXPERIMENTAL HEMATOLOGY, 2010, 38 (12) : 1189 - 1198
[43] FERRITIN AS A PROGNOSTIC FACTOR OF MULTIPLE MYELOMA
Chung, J. S.
Song, M. K.
Cho, G. J.
Choi, Y. J.
Kwon, B. R.
Seol, Y. M.
Joo, Y. D.
Yang, Y. S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 618 - 618
[44] V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
Mutsaers, Pim
Balcioglu, Hayri E.
Kuiper, Rowan
Hammerl, Dora
Wijers, Rebecca
van Duin, Mark
van der Holt, Bronno
Broijl, Annemiek
Gregory, Walter
Zweegman, Sonja
Sonneveld, Pieter
Debets, Reno
CANCERS, 2021, 13 (09)
[45] A Gene Expression-Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma
Hose, D.
Reme, T.
Hielscher, T.
Moreaux, J.
Meissner, T.
Seckinger, A.
Benner, A.
Hundemer, M.
Shaughnessy, J. D., Jr.
Barlogie, B.
Hillengass, J.
Bertsch, U.
Jauch, A.
Rossi, J. F.
Moehler, T.
Klein, B.
Goldschmid, H.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S98 - S98
[46] Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor
Vela-Ojeda, J.
Garcia-Ruiz Esparza, M. A.
Padilla-Gonzalez, Y.
Sanchez-Cortes, E.
Garcia-Chavez, J.
Montiel-Cervantes, L.
Reyes-Maldonado, E.
Majluf-Cruz, A.
Mayani, H.
ANNALS OF HEMATOLOGY, 2009, 88 (01) : 59 - 66
[47] Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma
Maillet, Daniela
Montiel-Cervantes, Laura
Padilla-Gonzalez, Ysabel
Sanchez-Cortes, Evelia
Xolotl-Castillo, Moises
Vela-Ojeda, Jorge
Reyes-Maldonado, Elba
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (01): : 17 - 24
[48] Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor
J. Vela-Ojeda
M. A. García-Ruiz Esparza
Y. Padilla-González
E. Sánchez-Cortes
J. García-Chávez
L. Montiel-Cervantes
E. Reyes-Maldonado
A. Majluf-Cruz
H. Mayani
Annals of Hematology, 2009, 88 : 59 - 66
[49] Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma
Xu, Limei
Liu, Junru
Chen, Meilan
Kuang, Lifen
Huang, Beihui
Gu, Jingli
Li, Juan
ANNALS OF HEMATOLOGY, 2020, 99 (03) : 581 - 589
[50] Circulating proteasome level is an independent prognostic factor for survival in patients with multiple myeloma.
Jakob, C
Egerer, K
Feist, E
Zavrski, I
Eucker, J
Heider, U
Burmester, G
Possinger, K
Kloetzel, PM
Sezer, O
BLOOD, 2004, 104 (11) : 415A - 415A

← 1 2 3 4 5 →